ASCO 2022 | Reducing the side effects associated with BTK inhibitors
Kerry Rogers
• 4 Jun 2022
Kerry Rogers, MD, The Ohio State University, Columbus, OH, gives an overview of strategies to limit the side effects of taking Bruton’s tyrosine kinase (BTK) inhibitors such as ibrutinib and venetoclax. Limiting exposure can reduce the longer term side effects such as hypertension and atrial fibrillation, and limiting the dosage can decrease immediate side effects such as bleeding. Using BTK inhibitors with alternative mechanisms of action such as acalabrutinib and zanubrutinib may also minimize side effects associated with taking certain BTK inhibitors. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
